Creutzfeldt-Jakob disease and plasma-derived and urine-derived medicinal products

  • Email
  • Help
Current version

Revision 2 - Position statement

Reference numberCHMP/BWP/303353/2010
Published28/06/2011
KeywordsCreutzfeldt-Jakob disease, human transmissible spongiform encephalopathies, plasma-derived medicinal products, urine-derived medicinal products, sporadic CJD, genetic CJD, iatrogenic CJD, variant CJD, blood infectivity, transmissibility
DescriptionThis document addresses the safety of plasma-derived and urine-derived medicinal products with respect to Creutzfeldt-Jakob disease (CJD). It gives special consideration to variant Creutzfeldt-Jakob disease (vCJD) infectivity.


Document history

Revision 2

Current version

Position statement


Overview of comments


Draft position statement


Concept paper

Published: 28/06/2011


Published: 28/06/2011


Published: 27/07/2010


Published: 23/07/2009

Revision 1Position statementPublished: 23/06/2004
First versionPosition statementPublished: 20/02/2003
Superseded documentPosition statementPublished: 25/02/1998


Related content


How helpful is this page?

Average rating:

 Based on 0 ratings

Add your rating:

See all ratings
0 ratings
0 ratings
0 ratings
0 ratings
0 ratings
    

Tell us more